A Phase 1-2 Study of PRT-201 Administered in Chronic Kidney Disease (CKD) Patients

Exclusion Criteria

• •Patients for whom this is the only potential site for an AVF.
• •By physical examination, absence of radial or ulnar artery flow or non-patent palmer arch.
• •Treatment with any investigational agent within the previous 30 days or investigational antibody therapy within 90 days of signing informed consent.
• •Pregnancy, lactation or plans to become pregnant during the course of the study.